Sylvie Grégoire
Director/Board Member presso NOVO NORDISK A/S
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Sylvie Louise Grégoire is the founder and currently holds multiple positions.
She is the Executive Chairman of EIP Pharma, Inc. which was founded in 2010.
She is also the Chairman of Corvidia Therapeutics, Inc. since 2016, an Independent Director at Novo Nordisk A since 2015, a Director at F2G Ltd., a Director at Revvity BV, a Director at CervoMed, Inc. since 2023, and a Member-Supervisory Board at Shire Orphan Therapies GmbH.
In her former positions, Dr. Grégoire served as the President, CEO & Executive Director of GlycoFi, Inc. from 2004 to 2005.
She was the Chairman of Metriopharm AG and the Executive Chairman of IDM Pharma, Inc. from 2005 to 2007.
She also served as an Independent Director at Cubist Pharmaceuticals LLC from 2006 to 2011.
Additionally, she held various director positions at Thallion Pharmaceuticals, Inc., CellCarta Biosciences, Inc., Vifor Pharma Management AG, Novo Nordisk Ltd., and Galenica AG.
She was also the President of the Human Genetic Therapies Division at Shire Plc and Shire Human Genetic Therapies, Inc. from 2007 to 2013.
Dr. Grégoire obtained a doctorate degree from the State University of New York at Buffalo in 1986.
She also holds an undergraduate degree from Université Laval, conferred in 1984, and an undergraduate degree from Séminaire de Sherbrooke, conferred in 1980.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
REVVITY, INC.
0.02% | 15/05/2023 | 20 482 ( 0.02% ) | 2 M $ | 31/03/2024 |
CERVOMED INC.
-.--% | 26/01/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Sylvie Grégoire
| Società | Posizione | Inizio |
|---|---|---|
| REVVITY, INC. | Director/Board Member | 06/02/2015 |
| NOVO NORDISK A/S | Director/Board Member | 19/03/2015 |
| CERVOMED INC. | Director/Board Member | 07/02/2024 |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Director/Board Member | - |
Revvity BV
 Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | Director/Board Member | - |
EIP Pharma, Inc.
 EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | Founder | 01/01/2010 |
Corvidia Therapeutics, Inc.
 Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Chairman | 14/06/2016 |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Director/Board Member | 27/05/2010 |
Precedenti posizioni note di Sylvie Grégoire
| Società | Posizione | Fine |
|---|---|---|
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 01/01/2013 |
| ░░░░░ ░░░░░ ░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Sylvie Grégoire
| State University of New York at Buffalo | Doctorate Degree |
| Université Laval | Undergraduate Degree |
| Séminaire de Sherbrooke | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| BIOGEN INC. | Health Technology |
| REVVITY, INC. | Health Technology |
| NOVO NORDISK A/S | Health Technology |
| GALENICA AG | Distribution Services |
| Aziende private | 18 |
|---|---|
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
Metriopharm AG
 Metriopharm AG Pharmaceuticals: MajorHealth Technology Metriopharm AG engages in the development and manufacture of pharmaceutical products. It offers pipeline, indicators and clinical trials. The company was founded by Ekkehard Brysch and Wolfgang Brysch in 2007 and is headquartered in Zurich, Switzerland. | Health Technology |
Vifor Pharma AG
 Vifor Pharma AG Pharmaceuticals: MajorHealth Technology Vifor Pharma AG is a pharmaceutical company, which engages in the research, development, production, and marketing of therapeutic products. It operates through the following geographical segments: Switzerland, Europe, USA, Rest of World, and Group. The firm offers products for iron deficiency, nephrology, and cardio-renal therapies. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. The company was founded in 1927 and is headquartered in St. Gallen, Switzerland. | Health Technology |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Health Technology |
GlycoFi, Inc.
 GlycoFi, Inc. BiotechnologyHealth Technology GlycoFi, Inc. develops biopharmaceutical products. It provides protein production technology to develop, produce and commercialize biotherapeutics products. The company was founded by Tillman Gerngross in 2000 and is headquartered in Lebanon, NH. | Health Technology |
IDM Pharma, Inc.
 IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | Health Technology |
Thallion Pharmaceuticals, Inc.
 Thallion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thallion Pharmaceuticals, Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology. Its products are Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections and TLN-4601, a proprietary first in class small molecule with potential efficacy in multiple oncology indications. The company was founded in January 1998 and is headquartered in Dorval, Canada. | Health Technology |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
CellCarta Biosciences, Inc.
 CellCarta Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services CellCarta Biosciences, Inc. develops proteomics and immune monitoring services. The firm offers integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its services include biomarker discovery, cell engine software, cellular enumeration, clinical laboratory services, functional profiling, host cell proteins detection, phenotyping characterization and receptor occupancy. The company was founded by Martin LeBlanc in 2000 and is headquartered in Montréal, Canada. | Commercial Services |
Vifor Pharma Management AG
 Vifor Pharma Management AG Pharmaceuticals: MajorHealth Technology Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland. | Health Technology |
Revvity BV
Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | Health Technology |
Novo Nordisk Ltd.
 Novo Nordisk Ltd. Medical/Nursing ServicesHealth Services Novo Nordisk Ltd. engages in the sale and marketing of pharmaceutical products for the treatment of chronic conditions in the United Kingdom. It offers medicines for the treatment of diabetes, and hemophilia and bleeding disorders, as well as for growth hormone therapy and hormone replacement therapy. The company is headquartered in Crawley, the United Kingdom. | Health Services |
EIP Pharma, Inc.
EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | Health Technology |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Health Technology |
| CervoMed, Inc. |
- Borsa valori
- Insiders
- Sylvie Grégoire
